



VRL/SEC/BSE/91

April 26, 2011

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai

Dear Sir/Madam,

**Sub. : Venus Remedies successfully completes Phase I & II Clinical Trials of  
TUMATREK (VRP1620), cancer detection molecule**

This is to inform you that the Company has successfully completed Phase I & II clinical trial for VRP1620, a cancer detection molecule. The clinical study has shown excellent results in detection of breast cancer. With this drug detection of breast cancer would be possible even with a simple X-ray using dye and the sensitivity of other detection devices such as colored doppler, PET would be increased several times.

VRP 1620 (Tumatrek) is a unique and cost effective diagnostic tool for cancer which can also detect malignancy even through X-ray. It can detect cancer at lesser cost and at primary stage itself. By detection of cancer at early stage it can increase the cure rate. Scientists believe that after Phase III trials of this product VRP-1620 may also help in locating proliferation of cancer site. There are lots of opportunities where the usage of this product can be extrapolated for the benefit of humanity.

A team of scientists from Venus Medicines Research Center (VMRC), R & D wing of the company were working for past couple of years on a novel peptide VRP 1620, which is highly selective ETB receptor agonist and is involved in selective vasodilation in solid tumors. Phase III will be completed this year only and product will be ready for market launch in early 2012.

The Company has completed and submitted the report of Phase I & II study on breast cancer patients for VRP 1620 after due permission from IND Committee and DCGI, Govt. of India. Phase I was conducted at the prestigious Postgraduate Institute of

Medical Education and Research (PGIMER) Chandigarh to find the maximum tolerable dose. Later Phase II clinical study was conducted at multiple institutions throughout India including PGIMER, Chandigarh and Central India Cancer Research Institute, Nagpur, Maharashtra. This clinical study documented the pharmacokinetic profile and appropriate

## VENUS REMEDIES LIMITED

**Corporate Office :**  
51-52, Industrial Area, Phase-1,  
Panchkula (Hry.) 134113, India  
**Regd. Office :**  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India  
**Website :** [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)

**M**  
**MOODY**  
INTERNATIONAL



**Unit-I :**  
51-52, Industrial Area, Phase-1, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
**Unit-II :**  
Hill Top Industrial Estate, Jharmajra EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272  
**Unit-III :**  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany



dose range for the drug. It also described the efficacy for its use as a diagnostic agent for breast cancer. The efficacy was gauged by observing increase in diameter and the corresponding change in resistive index of tumor vessel. An increase of 17.31 per cent in tumor vessel diameter was observed compared to baseline 12-15 minutes after drug administration of VRP-1620 at dose levels 0.8 µg / Kg body weight. Corresponding to this increase in tumor vessel diameter there was a decrease in RI (resistive index) 7.15 per cent. These changes indicate an increase in tumor blood perfusion causing the contrast media to deeply penetrate, creating a better tumor silhouette.

Tolerability of VRP 1620 was also assessed by the investigators and subjects at the end of study treatment period, which showed that the product is well tolerated.

Cancer prevalence in India is estimated to be around 2.5 million, with over 8,00,000 new cases and 5,50,000 deaths occurring each year due to this disease. More than 70 per cent of the cases report for diagnostic and treatment services in the advanced stages of the disease, which has lead to a poor survival and high mortality rate. Product has huge potential in urban and semi urban belts where advanced technologies of cancer detection are not available. This technology will provide a cutting edge in timely detection of cancer and has tremendous need specially in under developed and developing countries.

The global cancer market was worth \$56.7billion in 2007, growing at 16.8 per cent over 2006, and is forecast to reach a value of \$76.9 bn by 2013 representing a CAGR of 5.1per cent (2007-13). Oncology is one of the leading therapeutic categories in the global pharmaceutical market. The Indian Oncology Market is estimated to be about Rs 7,000 to 8,000 million. It has been indicated that the oncology market in India has been growing at a CAGR of more than 30 per cent in the last three years. The economic toll from cancer, estimated to be 895 billion dollars, is nearly 20 per cent higher than heart disease, the second leading cause of economic loss (\$753 billion).

Yours faithfully,  
for VENUS REMEDIES LIMITED

  
Rakesh Pandit  
DGM-Investor Relations

## VENUS REMEDIES LIMITED

**Corporate Office :**  
51-52, Industrial Area, Phase- I,  
Panchkula (Hry.) 134113, India

**Regd. Office :**  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

**Website :** [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



**Unit-I :**  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

**Unit-II :**  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhacoli Kalan, Baddi (H.R) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

**Unit-III :**  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany